secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-06-02T20:30:16+00:00
Accession:  0001193125-26-253604
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Therapeutics shareholders elect Ian Clark and Christi Shaw as Class II directors, ratify BDO USA auditor
--------------------------------------------------------------------------------

- 73% of outstanding shares (43.99M of 60.53M) represented at May 27, 2026 annual meeting, forming quorum.
- Ian Clark elected as Class II director: 31,505,902 for, 3,255,231 withheld, 9,225,874 broker non-votes.
- Christi Shaw elected as Class II director: 34,528,865 for, 232,268 withheld, 9,225,874 broker non-votes.
- BDO USA ratified as independent auditor for FY 2026: 43,830,300 for, 80,223 against, 76,484 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/0001193125-26-253604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/kytx-20260527.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-253604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer